P-Glycoprotein Expression in De Novo Acute Myeloid Leukemia

References

• Kartner N., Riodan J.R., Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983; 222: 1285–1288
   Web of Science ®Google Scholar
• Ma D.D.F., Davey R.A., Harman D.H., Ibister J.P., Scurr R.D., Mackertich S.M., Dowden G., Bell D.R. Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia. Lancet 1987; 1: 135–137
   PubMed Web of Science ®Google Scholar
• Holmes J., Jacobs A., Carter G., Janowska-Wieczorek A., Padua R.A. Multidrug resistance in hemopoietic cell lines, myelodisplastic syndromes and acute myeloblasts leukaemia. Br J Haematol 1989; 72: 40–44
   PubMed Web of Science ®Google Scholar
• Carulli G., Petrini M., Marini A., Ambrogi F. P-glycoprotein in acute non-lymphoblastic leukemia and in the blastic crisis of myeloid leukemia. N Engl J Med 1988; 319: 797–798
   PubMed Web of Science ®Google Scholar
• Marie J.P., Zittoun R., Siki B. Multidrug resistance (MDR1) gene expression in adult acute leukemia: Correlation with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586–592
   PubMed Web of Science ®Google Scholar
• Muller M.R., Lennartz K., Boogen C., Nowrousian M.R., Rajewsky M.F., Seeber S. Cytotoxicity of adri-amycin, idarubicin and vincristine in acute myeloid leukaemia: Chemosensitisation by verapamil in relation to P-glycoprotein expression. Ann Hematol 1992; 65: 206–212
   PubMed Web of Science ®Google Scholar
• Pirker R., Wallner J., Geissler K., Linkesch W., Haas O.A., Bettelheim P., Hopfher M., Scherrer R., Valent P., Havelec L., Ludwig H., Lechner K. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991; 83: 708–712
   PubMed Web of Science ®Google Scholar
• Sato H., Preisler H., Day R., Raza A., Larson R., Browman G., Goldberg J., Vogler R., Grunwald H., Gottlieb A., Bennett J., Gottesman M., Pastan I. MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br J Haematol 1990; 73: 340–345
   Web of Science ®Google Scholar
• Zhou D.C., Marie J.P., Suberville A.M., Zittoun R. Relevance of mdrl gene expression in acute myeloid leukaemia and comparison of different diagnostic methods. Leukemia 1992; 6: 879–885
   PubMed Web of Science ®Google Scholar
• Solary E., Bida J.M., Calvo F., Chauffert B., Caillot D., Mugneret F., Gauville G., Tsuruo T., Carli P.M., Guy H. P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and myeloma. Leukemia 1991; 5: 592–597
   PubMed Web of Science ®Google Scholar
• Campos L., Guyotat D., Archimbaud E., Calmard-Oriol P., Tsuruo T., Troncy J., Treille D., Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473–476
   PubMed Web of Science ®Google Scholar
• Arceci R.J. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993; 81: 2215–2222
   PubMed Web of Science ®Google Scholar
• Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735–7738
   PubMed Web of Science ®Google Scholar
• Nooter K., Herweijer H. Multidrug resistance (mdr) geners in human cancer. Br J Cancer 1991; 63: 663–669
   PubMed Web of Science ®Google Scholar
• Ito Y., Tanimoto M., Kumazawa T., Okumura M., Morishima Y., Ohno R., Saito H. Increased P-glycoprotein expression and multidrug-resistance gene (mdr1) amplification are infrequently found in fresh acute leukemia cells. Sequential analysis of 15 cases at initial diagnosis and relapsed stage. Cancer 1989; 63: 1534–1538
   PubMed Web of Science ®Google Scholar
• Mizuno J., Hara T., Nagata M., Tawa A., Tsuruo T., Ueda K. Detection of multidrug resistance protein, P-glycoprotein in childhood leukaemia and lymphoma. Eur J Pediatr 1991; 150: 416–418
   PubMed Web of Science ®Google Scholar
• Sugawara I., Kodo H., Ohkochi E., Hamadas H., Tsuruo T., Mori S. High-level expression of MRK 16 and MRK 20 murine monoclonal antibody-defined proteins (170,000–180,000 P-glycoprotein and 85,000 protein) in leukaemias and malignant lymphomas. Br J Cancer 1989; 60: 538–541
   PubMed Web of Science ®Google Scholar
• Ino T., Miyazaki H., Isogai M., Nomura T., Tsuzuki M., Tsuruo T., Ezaki K., Hirano M. Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: results of molecular and functional assays and correlation with treatment outcome. Leukemia 1994; 8(9)1492–1497
   PubMed Web of Science ®Google Scholar
• Michieli M., Damiani D., Geromin A., Michelutti A., Fanin R., Raspadori D., Russo D., Visani G., Dinota A., Piled S., Tsuruo T., Grandi M., Baccarani M., Tura S. Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukaemia. Eur J Haematol 1992; 48: 87–92
   PubMed Web of Science ®Google Scholar
• Venditti A., Del Poeta G., Buccisano F., Tamburtni A., Cox C., Stasi R., Bruno A., Aronica G., Maffei L., Suppo G., Simone M.D., Forte L., Cordero V., Postorino M., Tufilli V., Isacchi G., Masi M., Papa G., Amadori S. Minimally differentiated acute myeloid leukemia (AML-M0): Comparison of 25 cases with other FAB subtypes. Blood 1997, (in press)
   Web of Science ®Google Scholar
• Stasi R., Tribalto M., Venditti A., Del Poeta G., Aronica G., Zaccari G., Rossi V., Maffei L., Papa G. Simultaneous occurrence of monoclonal gammopathy and acute secondary leukemia with overexpression of P-glycoprotein. Tumori 1992; 78: 403–406
   PubMed Web of Science ®Google Scholar
• Del Poeta G., Stasi R., Venditti A., Suppo G., Aronica G., Bruno A., Masi M., Tabilio A., Papa G. Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia 1994; 8(3)388–394
   PubMed Web of Science ®Google Scholar
• Kartner N., Everden-Poreille D., Bradley G., Ling V. Detection of P-glycoprotein in multidrug resistant cell lines by monoclonal antibodies. Nature 1985; 316: 820–823
   PubMed Web of Science ®Google Scholar
• Scheper R.J., Bulte J.W.M., Brakker J.G.P., Quack J.J., Schoot Van Der E., Balm A.J.M., Meijer C. J. L. M., Broxterman H.J., Kuiper C.M., Lankelma J., Pinedo H.M. Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multidrug resistance. Br J Cancer 1988; 42: 389–394
   Web of Science ®Google Scholar
• Grandi M., Geroni C., Giuliani F.C. Isolation and characterization of a human colon adenocarcinoma cell line resistant to doxorubicin. Br J Cancer 1986; 54: 515–518
   PubMed Web of Science ®Google Scholar
• Dalton W.S., Grogan T.M., Rybski J.A., Scheper R.J., Richter L., Kailey J., Broxterman H.J., Pinedo H.M., Salmon S.E. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug resistant human myeloma cells: Association with level of drug resistance and drug accumulation. Blood 1989; 73: 747–752
   PubMed Web of Science ®Google Scholar
• Pileri S.A., Sabbatini E., Falini B., Tazzari P.L., Gherlinzoni F., Michieli M.G., Damiani D., Zucchini L., Gobbi M., Tsuruo T., Baccarani M. Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology 1991; 19: 131–140
   PubMed Web of Science ®Google Scholar
• Ludescher C., Thaler J., Drach D., Drach J., Spitaler M., Gattringer C., Huber H., Hofmann J. Detection of activity of P-glycoprotein in human tumor samples using rhodamine 123. Br J Haematol 1992; 82: 161–168
   PubMed Web of Science ®Google Scholar
• Stasi R., Del Poeta G., Masi M., Tribalto M., Venditti A., Papa G., Nicoletti B., Vernole P., Tedeschi B., Delaroche I., Mingarelli R., Dallapiccola B. Incidence of chromosome abnormalities and clinical significance of karyo-type in de novo acute myeloid leukemia. Cancer Genet Cytogenet 1993; 67: 28–34
   PubMed Web of Science ®Google Scholar
• Resegotti L, For the GIMEMA Group. Treatment of acute nonlymphoid leukemia (ANLL) in elderly patients. The GIMEMA experience. Leukemia 1992; 6: 72–75, (suppl 2)
   PubMed Web of Science ®Google Scholar
• Avvisati G., Petti M.C., Spadea A., Lazzarino M., Alessandrino E.P., Liso V., Specchia G., Carella A.M., Falda M., Fioritoni G., Ladogana F., Mandelli F, For the cooperative group GIMEMA. Idarubicin (IDA) treatment in acute promyelocytic leukemia (APL): the GIMEMA experience. Haematologica 1991; 76: 10, (suppl 4)
   PubMedGoogle Scholar
• Zittouh R., Mandelli F., Willemze R., De Witte T., Labar B., Resegotti L., Leoni F., Damasio E., Visani G., Papa G., Caronia F., Hayat M., Stryckmans P., Rotoli B., Leoni P., Peetermans M., Dardenne M., Vegna M.L., Petti M.C., Solbu G., Suciu S, For the EORTC and the GIMEMA Leukemia Cooperative Groups. Autologous or allogeneic bone marrow tranplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332: 217–223
   PubMed Web of Science ®Google Scholar
• Zittoun R., Liso V., Mandelli F., Rotoli B., De Witte T., Gattringer C., Resegotti L., Caronia F., Leoni P., Petti M.C., Solbu G., Vegna M.L., Suciu S, For the EORTC Leukemia Cooperative Group and the GIMEMA Group. Intensive consolidation chemotherapy vs. standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC- Gimema phase III trial (AML 8B). Leukemia 1992; 6: 76–77, (suppl 2)
   PubMed Web of Science ®Google Scholar
• Heil G., Hoelzer D., Sanz M.A., Lechner K., Liu Yin J., Papa G., Noens L., Ho J., O'Brien C., Matcham J., Barge A. on behalf of the AML study group in Germany, Spain, Austria, United Kingdom, Italy, Belgium, Australia, Sweden and Portugal. Results of a randomised, double blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de-novo acute myeloid leukemia. Blood 1995; 86: 1053, (abstr)
   Web of Science ®Google Scholar
• Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.G., Gralnick H.R., Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985; 103: 620–625
   PubMed Web of Science ®Google Scholar
• Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton A.G., Gralnick H.R., Sultan C. Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-M0). Br J Haematol 1991; 78: 325–329
   PubMed Web of Science ®Google Scholar
• Muller M.R., Lennartz K., Nowrousian M.R., Dux R., Tsuruo T., Rajewsky M.F., Seeber S. Improved flow-cytometric detection of low P-glycoprotein expression in leukaemic blasts by histogram subtraction analysis. Cytometry 1994; 15: 64–72
   PubMedGoogle Scholar
• Hart S.M., Ganeshaguru K., Lyttelton M.P., Prentice H.G., Hoffbrand A.V., Mehta A.B. Flow cytometric assessment of multidrug resistance (MDR) phenotype in acute myeloid leukaemia. Leuk-Lymphoma 1993; 11: 239–248
   PubMed Web of Science ®Google Scholar
• Miwa H., Kita K., Nishii K., Morita N., Takakura N., Ohishi K., Mahmud N., Kageyama S., Fukumoto M., Shirakawa S. Expression of MDR1 gene in acute leukemia cells: Association with CD7+ acute myeloblasts/acute lymphoblastic leukemia. Blood 1993; 82: 3445–3451
   PubMed Web of Science ®Google Scholar
• Schinkel A.H., Roelofs M.E.M., Borst P. Characterization of human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Res 1991; 51: 2628–2635
   PubMed Web of Science ®Google Scholar
• Thiebault F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Immunocyto-chemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and cross-reactivity of one antibody with a muscle protein. J Histochem Cytochem 1989; 37: 159–164
   PubMed Web of Science ®Google Scholar
• Cenciarelli C., Currier S.J., Willingham M.C., Thiebaut F., Germann U.A., Rutheford A.V., Gottesman M.M., Barca S., Tombesi M., Morrone S., Santoni A., Mariani M., Ramoni C., Dupuis M.L., Cianfriglia M. Characterization by somatic cell genetics of a monoclonal antibody to the MDR1 gene product (P-glycoprotein): determination of P-glycoprotein expression in multi-drug resistant KB and CEM cell variants. Int J Cancer 1991; 47: 533–543
   PubMed Web of Science ®Google Scholar
• Hamada H., Tsuruo T. Functional role for the 170–180 kDa glycoprotein in drug resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 1986; 83: 7785–7789
   PubMed Web of Science ®Google Scholar
• Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735–7738
   PubMed Web of Science ®Google Scholar
• Xie X.-Y., Robb D., Chow S., Hedley D.W. Discordant P-glycoprotein antigen expression and transport function in acute myeloid leukemia. Leukemia 1995; 9: 1882–1887
   PubMed Web of Science ®Google Scholar
• Ferrand V.L., Montero Julian F.A., Chauvet M.M., Him M.H., Bourdeaux M.J. Quantitative determination of the MDR-related P-glycoprotein, PgP 170, by a rapid flow cytometric technique. Cytometry 1996; 23: 120–125
   PubMedGoogle Scholar
• Nuessler V., Pelka-Fleischer R., Nerl C., Beckert B., Wilmanns W. P-glycoprotein expression in patients with acute leukemia, chronic leukemia and myelodysplastic syndromes. J Cancer Res Clin Oncol 1991; 117: S114, (Suppl 3)
   Google Scholar
• Sato H., Gottesman M.M., Goldstein L.J., Pastan I., Block A.M., Sandberg A.A., Preisler H.D. Expression of the multidrug resistance gene in myeloid leukemias. Leuk Res 1990; 14: 11–22
   PubMed Web of Science ®Google Scholar
• Musto P., Melillo L., Lombardi G., Matera R., Di Giorgio G., Carotenuto M. High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br J Haematol 1991; 77: 50–53
   PubMed Web of Science ®Google Scholar
• Paietta E., Andersen J., Racevskis J., Gallagher R., Bennett J., Yunis J., Cassileth P., Wiernik P.H. Significantly lower P-glycoprotein expression in acute promyelocitic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia 1994; 8(6)968–973
   PubMed Web of Science ®Google Scholar
• Fojo A., Lebo R., Shimizu N., Chin Je, Roninson I.B., Merlino G.T., Gottesman M.M., Pastan I. Localization of multidrug resistance associated DNA sequences to human chromosome 7. Somatic Cell Mol Genet 1986; 12: 415–420
   PubMedGoogle Scholar
• Kuss B.J., Deeley R.G., Cole S.P., Willman C.L., Kopecky K.J., Wolman S.R., Eyre H.J., Lane S.A., Nancarrow J.K., Whitmore S.A. Deletion of gene for multidrug resistance in acute myeloid leukemia with inversion of chromosome 16: prognostic implications. Lancet 1994; 343: 1531–1534
   PubMed Web of Science ®Google Scholar
• Del Poeta G., Stasi R., Aronica G., Venditti A., Cox M.C., Bruno A., Buccisano F., Masi M., Tribalto M., Amadori S., Papa G. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 1996; 87: 1997–2004
   PubMed Web of Science ®Google Scholar
• Te Boekhorst P.A.W., De Leeuw K., Schoester M., Wittebol S., Nooter K., Hagemeijer A., Lowenberg B., Sonneveld P. Predominance of functional multidrug resistance (mdr-1) phenotype in CD34+ acute myeloid leukemia cells. Blood 1993; 85: 3157–3162
   Google Scholar
• Leith P.C., Chen M.I., Kopecky K.J., Appelbaum F.R., Head D.R., Godwin J.E., Weick J.K., Willman C.L. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR+/efflux-cases. Blood 1995; 86: 2329–2342
   PubMed Web of Science ®Google Scholar
• Kuwazuru Y., Yoshimura A., Hanada S., Utsunomiya A., Makino T., Ishibashi K., Kodama M., Iwahashi M., Arima T., Akiyama S.I. Expression of the multidrug transporter P-glycoprotein in acute leukemia cells and correlation to clinical drug resistance. Cancer 1990; 66: 868–873
   PubMed Web of Science ®Google Scholar
• Herweijer H., Sonneveld P., Baas F., Nooter K. Expression of MDR1 and MDR3 multidrug resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporin. J Natl Cancer Inst 1990; 82: 1133–1140
   PubMed Web of Science ®Google Scholar
• Goldstein L.J., Hanan G., Fojo A., Willingham M., Lai S.L., Gazdar A., Pirker R., Green A., Crist W., Brodeur G.M., Lieber M. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116–124
   PubMed Web of Science ®Google Scholar